Clinical Trials Browser

Interventional × Vaccinia × Gynecologic × Clear all

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

186 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

Phase 1 Recruiting

78 enrolled

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Vaccinia, Colorectal Neoplasms

NCT01443260 2025-04-30

A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis

Phase 1/2 Completed

9 enrolled

Gynecologic

Neoplasms, Peritoneal Neoplasms, Vaccinia

NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Phase 1/2 Completed

46 enrolled

Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases

NCT02017678 2014-09-17

Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin

Phase 2 Withdrawn

Gynecologic

Carcinoma, Ovarian Neoplasms, Vaccinia